May 1, 2010Journal of Cardiovascular Medicine
Myocardial scarring following chemotherapy for multiple myeloma detected using late gadolinium hyperenhancement cardiovascular magnetic resonance
Key result
Bortezomib for multiple myeloma is linked to heart failure and midwall myocardial fibrosis on CMR.
Why the study?
Myocardial scarring following chemotherapy for multiple myeloma and its detection by cardiovascular magnetic resonance is not well characterized.
Population
60-year-old female treated with chemotherapy for multiple myeloma who developed heart failure
Design
Case report
Authors
Discussion
Loading...
Member takes
Implication
May warrant LV monitoring during bortezomib; this Level 5 case leaves open causality and need for prospective confirmation.
Structured PICO
P
Population
60-year-old female treated with chemotherapy for multiple myeloma who developed heart failure (n=1)
I
Intervention
Gadolinium enhanced cardiovascular magnetic resonance scan
O
Outcome
Detection of myocardial scarring/midwall fibrosissurrogate
Late gadolinium enhancement cardiovascular magnetic resonance can detect midwall fibrosis in patients developing heart failure after bortezomib chemotherapy.
Cite This Study
Foley et al. (2010) studied this question. Bortezomib chemotherapy for multiple myeloma was associated with heart failure and midwall myocardial fibrosis detected by gadolinium-enhanced cardiovascular magnetic resonance.